Increased infiltration of T and NK cells accompanied by reduced primary and metastatic tumor burden was also observed when combining AXL inhibitor, with anti-PD-1 therapy in preclinical settings of HER2-positive breast cancer suggesting that alleviating hypoxia can generate a potential therapeutic modality for HER2-positive patients whose tumors exhibit hypoxic signature [173]. Here, ERBB2 is linked to breast cancer.